NCT06977711: Loncastuximab and Roflumilast Added to R-CHOP (Lo-(Rituximab and Roflumilast) RR-CHOP) for Naïve High-Risk Diffuse Large B-cell Lymphoma (DLBCL) |
|
|
| Recruiting | 1 | 10 | US | Loncastuximab, Roflumilast, Rituximab, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone | The University of Texas Health Science Center at San Antonio | Diffuse Large B-cell Lymphoma | 04/26 | 07/26 | | |
NCT05796271: Clinical Trial of Roflumilast Added to Standard Chemoimmunotherapy |
|
|
| Withdrawn | 1 | 90 | US | R-Chop and Roflumilast, Daliresp | The University of Texas Health Science Center at San Antonio | Lymphoma, B-Cell | 01/27 | 01/28 | | |
